← Leaderboards
Erica A Golemis
Research Inst Of Fox Chase Can Ctr
$12,682,758
Attributed
$13,998,612
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $975.2K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,998,612 · 20
By mechanism
R01$8,430,147 · 4
R21$1,705,305 · 4
P50$1,493,086 · 1
P30$635,514 · 3
U54$612,511 · 1
R25$446,619 · 1
Top collaborators
- Andrew K Godwin5 shared
- Russell J Schilder5 shared
- Sara J. Ward2 shared
- Joseph M Salvino1 shared
Most similar at Research Inst Of Fox Chase Can Ctr
Same institution · by research overlap
- Margret B Einarson$636,468
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSignal TransductionProteinsInsightTumorResponseProgramsBaseCancer TherapyCellsLaboratoriesMolecularRegulationBioinformaticsPhosphotransferasesClinical TrialsScreeningOncogenicPre-ClinicalPharmaceutical PreparationsResearch PersonnelLibrariesPathway InteractionsFunding
Grant awards (64)
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni Syndrome$612,511
U54 · FY2025 · CA · contact PI
Pilot Studies of NN-01-195, a New Tumor-Targeted AURKA Inhibitor$186,000
R03 · FY2025 · CA · contact PI
High Throughput Screening Facility$45,444
P30 · FY2025 · CA · contact PI
Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways$199,821
R21 · FY2024 · CA · contact PI
Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development$79,694
R25 · FY2024 · CA · contact PI
Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways$255,105
R21 · FY2023 · CA · contact PI
Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development$151,756
R25 · FY2023 · CA · contact PI
Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development$215,169
R25 · FY2022 · CA · contact PI
Shared Resource: High Throughput Screening Facility$33,644
P30 · FY2021 · CA · contact PI
Molecular Therapeutics Program (04)$14,265
P30 · FY2021 · CA · contact PI
Interaction of protein-targeted therapeutics and ciliary dynamics$420,750
R01 · FY2020 · DK · contact PI
Targeting asymmetric ciliary signaling in cancer$203,363
R21 · FY2020 · CA · contact PI
Shared Resource: High Throughput Screening Facility$92,759
P30 · FY2020 · CA · contact PI
Molecular Therapeutics Program (04)$45,024
P30 · FY2020 · CA · contact PI
Shared Resource: High Throughput Screening Facility$8,696
P30 · FY2020 · CA · contact PI
Molecular Therapeutics Program (04)$8,695
P30 · FY2020 · CA · contact PI
Interaction of protein-targeted therapeutics and ciliary dynamics$411,750
R01 · FY2019 · DK · contact PI
Targeting asymmetric ciliary signaling in cancer$199,013
R21 · FY2019 · CA · contact PI
Shared Resource: High Throughput Screening Facility$86,782
P30 · FY2019 · CA · contact PI
Molecular Therapeutics Program (04)$42,123
P30 · FY2019 · CA · contact PI
Interaction of protein-targeted therapeutics and ciliary dynamics$411,750
R01 · FY2018 · DK · contact PI
Shared Resource: High Throughput Screening Facility$81,578
P30 · FY2018 · CA · contact PI
Shared Resource: High Throughput Screening Facility$10,869
P30 · FY2018 · CA · contact PI
Shared Resource: High Throughput Screening Facility$5,968
P30 · FY2018 · CA · contact PI
Interaction of protein-targeted therapeutics and ciliary dynamics$401,625
R01 · FY2017 · DK · contact PI
Msi2 regulates the aggressiveness of Non-Small Cell Lung Cancer (NSCLC)$232,943
R21 · FY2017 · CA · contact PI
Shared Resource: High Throughput Screening Facility$81,575
P30 · FY2017 · CA · contact PI
Interaction of protein-targeted therapeutics and ciliary dynamics$401,625
R01 · FY2016 · DK · contact PI
Msi2 regulates the aggressiveness of Non-Small Cell Lung Cancer (NSCLC)$194,119
R21 · FY2016 · CA · contact PI
Shared Resource: High Throughput Screening Facility$78,092
P30 · FY2016 · CA · contact PI
Multiplexing biomarker analyzer$75,919
S10 · FY2016 · OD · contact PI
A Role for AMH Autocrine Signaling in NSCLC$229,837
R21 · FY2015 · CA · contact PI
Interaction of protein-targeted therapeutics and ciliary dynamics$116,025
R56 · FY2015 · DK · contact PI
A Role for AMH Autocrine Signaling in NSCLC$191,104
R21 · FY2014 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$310,275
P50 · FY2013 · CA
HEF1 Coordination of Cell Cycle, Migration, and Invasion in Cancer$306,415
R01 · FY2013 · CA · contact PI
HEF1 Coordination of Cell Cycle, Migration, and Invasion in Cancer$324,971
R01 · FY2012 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$242,445
P50 · FY2012 · CA
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$323,787
P50 · FY2011 · CA
HEF1 Coordination of Cell Cycle, Migration, and Invasion in Cancer$318,618
R01 · FY2011 · CA · contact PI
Cas Protein Regulation of EMT in Cancer$293,155
R01 · FY2011 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$341,238
P50 · FY2010 · CA
HEF1 Coordination of Cell Cycle, Migration, and Invasion in Cancer$328,475
R01 · FY2010 · CA · contact PI
Cas Protein Regulation of EMT in Cancer$305,455
R01 · FY2010 · CA · contact PI
HEF1 Coordination of Cell Cycle, Migration, and Invasion in Cancer$321,275
R01 · FY2009 · CA · contact PI
Cas Protein Regulation of EMT in Cancer$304,984
R01 · FY2009 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$275,341
P50 · FY2009 · CA
Cas Protein Regulation of EMT in Cancer$290,163
R01 · FY2008 · CA · contact PI
HEF1 Functions in Cell Division-Related Signaling$421,270
R01 · FY2007 · CA · contact PI
Cas Protein Regulation of EMT in Cancer$292,099
R01 · FY2007 · CA · contact PI
HIF-1$69,790
P41 · FY2007 · RR · contact PI
HEF1 Functions in Cell Division-Related Signaling$422,450
R01 · FY2006 · CA · contact PI
HIF-1$81,307
P41 · FY2006 · RR · contact PI
HEF1 Functions in Cell Division-Related Signaling$304,650
R01 · FY2005 · CA
HIF-1$75,467
P41 · FY2005 · RR
HEF1 Functions in Cell Division-Related Signaling$306,000
R01 · FY2004 · CA
HIF-1$70,922
P41 · FY2004 · RR
HEI C AND MORPHOGENESIS AND SIGNALING$263,114
R01 · FY2003 · CA
ROLES OF HEF1 IN CELL DIFFERENTIATION AND SURVIVAL$285,094
R01 · FY2002 · CA
HEI C AND MORPHOGENESIS AND SIGNALING$255,451
R01 · FY2002 · CA
ROLES OF HEF1 IN CELL DIFFERENTIATION AND SURVIVAL$276,790
R01 · FY2001 · CA
HEI C AND MORPHOGENESIS AND SIGNALING$248,013
R01 · FY2001 · CA
ROLES OF HEF1 IN CELL DIFFERENTIATION AND SURVIVAL$268,731
R01 · FY2000 · CA
HEI C AND MORPHOGENESIS AND SIGNALING$245,474
R01 · FY2000 · CA